Evidence map›Paper›PMID 39984745›Full record

SynthesisEuropean journal of nuclear medicine and molecular imaging2025

Evaluating Xerostomia as a side effect of [

Akram Al-Ibraheem, Serin Moghrabi, Mike Machaba Sathekge, Ahmed Saad Abdlkadir

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Beyond [BMC cancer · 2026
    Pooled it
  3. Evaluation of the safety and efficacy ofEuropean radiology experimental · 2026
    Trial
  4. First-in-Human Study of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Trial
  5. Article
  6. Case Report: [Frontiers in oncology · 2026
    Article
  7. Future of radiotheranostics.BMJ oncology · 2026
    Review
  8. Review
  9. Pilot experience of [Theranostics · 2025
    Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Akram Al-IbraheemDepartment of Nuclear Medicine, King Hussein Cancer Center (KHCC), Queen Rania Street Al Jubeiha, Amman, 11941, Jordan. aibraheem@khcc.jo.ORCID 0000-0002-0978-4716
Serin MoghrabiDepartment of Nuclear Medicine, King Hussein Cancer Center (KHCC), Queen Rania Street Al Jubeiha, Amman, 11941, Jordan.
Mike Machaba SathekgeDepartment of Nuclear Medicine, University of Pretoria & Steve Biko Academic Hospital, Pretoria, 0001, South Africa.
Ahmed Saad AbdlkadirDepartment of Nuclear Medicine, King Hussein Cancer Center (KHCC), Queen Rania Street Al Jubeiha, Amman, 11941, Jordan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis systematic review and meta-analysis evaluates xerostomia occurrence in prostate cancer (PC) patients undergoing [

methodsFollowing the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) guidelines, comprehensive electronic searches were conducted across PubMed, Scopus, and Web of Science. The study included articles addressing xerostomia as a side effect of [

resultsTwenty studies met inclusion criteria, comprising 2949 [

conclusionXerostomia is most pronounced in patients undergoing [

Indexed as

ActiniumProstatic NeoplasmsXerostomiaHumansMaleActinium[225Ac]Ac-PSMADry mouthMeta-analysisTandemTargeted alpha therapyXerostomia

Identifiers

PMID39984745

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.